These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 3063171

  • 21. Mutations and/or Overexpressions of ERG4 and ERG11 Genes in Clinical Azoles-Resistant Isolates of Candida albicans.
    Feng W, Yang J, Xi Z, Qiao Z, Lv Y, Wang Y, Ma Y, Wang Y, Cen W.
    Microb Drug Resist; 2017 Jul; 23(5):563-570. PubMed ID: 27976986
    [Abstract] [Full Text] [Related]

  • 22. In vitro interaction between amphotericin B and azoles in Candida albicans.
    Vazquez JA, Arganoza MT, Vaishampayan JK, Akins RA.
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2511-6. PubMed ID: 8913455
    [Abstract] [Full Text] [Related]

  • 23. [Isolation, identification and drug-resistance of nosocomial yeasts].
    Alegente G, Gonnelli A, Galgani P, Boggiano CA.
    Ann Sclavo; 1982 Nov; 24(2):103-13. PubMed ID: 6763853
    [No Abstract] [Full Text] [Related]

  • 24. [Investigation of quantitative and species composition and antifungal drug susceptibility of yeasts isolated from patients with generalized periodontitis complicated by candidosis].
    Kutsyk RV, Pavliuk TD.
    Mikrobiol Z; 2003 Nov; 65(5):26-9. PubMed ID: 14723159
    [Abstract] [Full Text] [Related]

  • 25. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans.
    Liu TT, Lee RE, Barker KS, Lee RE, Wei L, Homayouni R, Rogers PD.
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2226-36. PubMed ID: 15917516
    [Abstract] [Full Text] [Related]

  • 26. Reduction of susceptibility to azoles and 5-fluorocytosine and growth acceleration in Candida albicans in glucosuria.
    Hiyama Y, Sato T, Takahashi S, Yamamoto S, Ogasawara N, Masumori N, Yokota SI.
    Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115556. PubMed ID: 34678714
    [Abstract] [Full Text] [Related]

  • 27. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
    Chokoeva A, Kouzmanov A, Ivanova Z, Zisova L, Amalie G, Petleshkova P, Miteva-Katrandzhieva T, Krasteva M, Uchikova E.
    Akush Ginekol (Sofiia); 2016 Jan; 55(4):20-29. PubMed ID: 29370489
    [Abstract] [Full Text] [Related]

  • 28. Multilocus sequence typing confirms synonymy but highlights differences between Candida albicans and Candida stellatoidea.
    Jacobsen MD, Boekhout T, Odds FC.
    FEMS Yeast Res; 2008 Aug; 8(5):764-70. PubMed ID: 18547330
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of amphotericin B and flucytosine against fluconazole-resistant Candida inconspicua clinical isolates.
    Majoros L, Kardos G, Feiszt P, Szabó B.
    J Antimicrob Chemother; 2005 Jul; 56(1):253-4. PubMed ID: 15911550
    [No Abstract] [Full Text] [Related]

  • 30. Using Galleria mellonella-Candida albicans infection model to evaluate antifungal agents.
    Li DD, Deng L, Hu GH, Zhao LX, Hu DD, Jiang YY, Wang Y.
    Biol Pharm Bull; 2013 Jul; 36(9):1482-7. PubMed ID: 23995660
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media.
    Siau H, Kerridge D.
    J Antimicrob Chemother; 1998 Mar; 41(3):357-66. PubMed ID: 9578162
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Penetration of Candida biofilms by antifungal agents.
    Al-Fattani MA, Douglas LJ.
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3291-7. PubMed ID: 15328087
    [Abstract] [Full Text] [Related]

  • 35. In vitro interactions of approved and experimental drugs against Candida drugs against Candida spp.
    Repp KK, Hogan F, Pettit GR, Pettit RK.
    J Chemother; 2008 Feb; 20(1):137-9. PubMed ID: 18343758
    [No Abstract] [Full Text] [Related]

  • 36. The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species.
    Bulo AN, Bradley SF, Kauffman CA.
    Mycoses; 1989 Jan; 32(1):46-52. PubMed ID: 2747742
    [Abstract] [Full Text] [Related]

  • 37. Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata.
    Kerridge D, Nicholas RO.
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():39-49. PubMed ID: 3539907
    [Abstract] [Full Text] [Related]

  • 38. In vitro antifungal resistance of oral Candida albicans strains in non-AIDS patients.
    Monteil RA, Madinier I, Le Fichoux Y.
    Oral Microbiol Immunol; 1997 Apr; 12(2):126-8. PubMed ID: 9227138
    [Abstract] [Full Text] [Related]

  • 39. In vitro method to study antifungal perfusion in Candida biofilms.
    Samaranayake YH, Ye J, Yau JY, Cheung BP, Samaranayake LP.
    J Clin Microbiol; 2005 Feb; 43(2):818-25. PubMed ID: 15695686
    [Abstract] [Full Text] [Related]

  • 40. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
    Melkusová S, Bujdáková H, Volleková A, Myoken Y, Mikami Y.
    Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.